Zhejiang Jianfeng Group(600668.SH): Application for the listing of Compound Tropicamide Eye Drops is not approved.

15:45 19/03/2026

Peak Group (600668.SH) announced that its wholly-owned subsidiary Zhejiang Peak Pharmaceutical Co., Ltd. (referred to as "Peak Pharma") received a "Notice of Disapproval of Drug Marketing Application" issued by the National Medical Products Administration for its compound tropicamide eye drops (0.5ml: tropicamide 2.5mg and epinephrine hydrochloride 2.5mg). The reason for the disapproval is as follows:

Zhejiang Jianfeng Group (600668.SH) announced that its wholly-owned subsidiary Zhejiang Jianfeng Pharmaceutical Co., Ltd. (referred to as "Jianfeng Pharmaceutical") received a "Notice of Disapproval of Drug Marketing Application" issued by the National Medical Products Administration for the compound tropicamide eye drops (0.5ml: tropicamide 2.5mg and hydrochloride norepinephrine 2.5mg). The reason is as follows: The provided research data cannot prove the rationality of the specifications of this product, which does not meet the requirements of the "Notice on the Issuance of 5 Drug Evaluation Technical Standards including Chemical Drug Technology Standards" (NMPA Announcement [2008] No. 271).

DATANG RENEW (01798) intends to exercise the redemption option of "23 Datang New Energy MTN001" issuer.

PICO FAR EAST (00752) exercised its rights to purchase shares, resulting in a total issuance of 1,158,000 shares.

SINOPEC CORP (00386) elects Wang Shijie as employee representative director.

DATANG RENEW (01798) intends to exercise the redemption option of "23 Datang New Energy MTN001" issuer.

PICO FAR EAST (00752) exercised its rights to purchase shares, resulting in a total issuance of 1,158,000 shares.

SINOPEC CORP (00386) elects Wang Shijie as employee representative director.